Introduction
Since the identification and cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989, 1,2 the goal of treating patients suffering from cystic fibrosis (CF) by gene transfer has been an area of intense research activity. Although much has been learned from these studies, the clinical trials conducted to date indicate that significant obstacles must be overcome before gene therapy for this often fatal disease is successful. 3, 4 Optimally, for gene therapy to correct a genetic defect, the expression of the normal transgene should occur in the same location and at the same level as the endogenous protein. This would not only provide sufficient levels of the normal protein product to complement the genetic defect, but also would prevent any unforeseen consequences of overexpression of the transgene in cell types not normally expressing the protein. In the human airway, CFTR has been reported to be expressed in ciliated cells and in serous cells of the submucosal glands. [5] [6] [7] [8] However, the exact cellular distribution of CFTR and the importance of different cell types to disease pathogenesis remain unclear. To express CFTR in the correct cells at the correct level, the use of the endogenous cellular promoter to drive expression of the transgene would be ideal. However, the endogenous promoter of the CFTR gene is very large, complex and only expresses CFTR at a very low level. 9 Thus it is unsuitable for use with the vector systems currently available, both because its size precludes its packaging into many vectors and because the efficiency of transducing well-differentiated airway epithelial cells is low, and may require a strong promoter to generate enough CFTR for functional correction.
As a result of these considerations, most studies of CFTR gene transfer have used highly active and ubiquitous promoters, such as the long-terminal repeat of Rous sarcoma virus or the combination of the cytomegalovirus enhancer and chicken b-actin promoter. 10, 11 While these promoters provide high levels of expression of CFTR or reporter genes, they lack specificity, and may not provide stable, long-term expression. 12 As an alternative, we and others have begun to investigate the use of endogenous, cell-type specific promoters to target the expression of CFTR to the airway epithelium where the CFTR protein is a critical regulator of the volume of airway surface liquid. 13 For example, Hu and co-workers 14 have developed an expression cassette using the promoter from the keratin 18 gene. Previously, we have demonstrated that a small fragment of the human FOXJ1 promoter is sufficient to target the expression of a reporter (enhanced green fluorescent protein (EGFP)) to the ciliated cells of the respiratory tract in a transgenic mouse model. 15 In this study, the same promoter construct was used to drive the expression of the human CFTR gene in transgenic mice. These animals were then crossed with CFTR null mice (Cftr tm1Unc ), 16 and the effect of expressing human CFTR targeted specifically to the ciliated cells was examined.
Results

Generation of FOXJ1/CFTR transgenic mice
To generate mice expressing CFTR specifically in ciliated cells, the EGFP cDNA in the previously described FOXJ1 construct 15 was replaced with the cDNA for human CFTR. 17 Transgenic mice were generated by standard procedures utilizing pronuclear injection and Southern blot analysis was used to identify transgene-positive founder animals that were bred to establish the lines used for these studies. One line (CFCF46) was extensively characterized, whereas a second, independent line (CFCF08) was used to replicate most findings.
Analysis of CFTR expression in tracheal epithelia
We first examined the expression of the CFTR transgene at the transcript level by performing reverse transcriptase-PCR (RT-PCR) using RNA isolated from several mouse tissues and primers specific for the human CFTR transgene. Tissues from transgene-positive animals that contained ciliated cells (tracheal and nasal) were positive for human CFTR expression, whereas tissues that did not contain ciliated cells (esophagus, liver and muscle) and all tissues from wild-type (WT) animals were negative by this assay (Figure 1a ). To determine the approximate level of transgene expression in the airway epithelia of transgenic animals, quantitative RT-PCR was performed. Total RNA was isolated from tracheas of transgenic animals and WT controls and the levels of mRNA were determined using primers specific for both mouse and human CFTR (Figure 1b) . The level of murine CFTR was unchanged in the transgenic animals, and averaged about 150 copies of CFTR/ng of RNA. As expected, no human CFTR was detected in the WT animals, while the transgenic animals expressed approximately eightfold higher levels of human CFTR than murine CFTR (approximately 1200 copies/ng RNA). These data demonstrate that the FOXJ1/CFTR promoter construct is expressed specifically in ciliated tissues and at levels substantially higher than the endogenous level of murine CFTR.
To demonstrate that the expressed transgene was being translated into CFTR protein, immunoprecipitation was performed on tracheal extracts using monoclonal antibodies specific for human CFTR. 18 Protein lysates were first incubated with an antibody against the Cterminus of human CFTR and following immunoprecipitation CFTR was detected by western blotting with an antibody against the second nucleotide binding domain (NBD2). As shown in Figure 1c , tracheal extracts from transgenic animals clearly produce protein reactive with the anti-CFTR monoclonal antibodies. By comparison to the banding pattern observed in Calu-3 cells, the majority of the CFTR protein in the transgenic animals appears to migrate as a higher molecular weight species, suggesting that this represents the mature, fully glycosylated form of CFTR (band C). In contrast, extracts from WT animals demonstrate only a weak background band.
To examine the cellular localization of the expressed transgene, frozen tracheal sections from FOXJ1/CFTR- 
CFTR transgene function in tracheal epithelia
The above experiments clearly demonstrated the expression of human CFTR in tracheal cells from the FOXJ1 promoter. We first tested whether the overexpression of CFTR in the ciliated tracheal epithelia of WT mice increased cAMP-mediated chloride secretion. Tracheas from WT and FOXJ1/CFTR transgenic mice were mounted in Ussing chambers and their response to forskolin was measured. No significant change in the forskolin response was detected in the transgenic animals (WT, 14.873.3 mA cm
À2
; n ¼ 7; FOXJ1/CFTR, 16.772.2 mA cm À2 , n ¼ 6). The FOXJ1/CFTR transgenic mice were then crossed to CFTR null animals to generate CF mice expressing human CFTR specifically in ciliated cells. Due to the presence of an alternative chloride channel, it is difficult to distinguish the bioelectric response of tracheas from CF null and WT animals. 19, 20 We also observed no difference in forskolin-stimulated current in tracheas isolated from WT, CF and FOXJ1/CFTR transgenic CF mice. However, in previous work (B Grubb, unpublished data), it was observed that in isolated tracheas from neonatal mice (from birth to approximately 3 days of age) studied in Ussing chambers, CFÀ/À mice could be distinguished from CF+/À animals on the basis of their response to forskolin stimulation. Immunostaining of neonatal tracheas again demonstrated that the majority of the human CFTR protein was localized at the apical domain of ciliated cells (Figure 3a) . Thus the bioelectrics of neonatal tracheas from CF+/À, CFÀ/À and CFÀ/À mice expressing human CFTR from the FOXJ1 transgene were compared. Under these conditions, tracheal tissue from the CFÀ/À mice demonstrated a reduced basal I sc , relative to CF+/À mice, and significant reduction in forskolin-stimulated current (Figure 3b ). Tracheal tissue from the FOXJ1/CFTR transgenic CFÀ/À mice demonstrated a correction of the CF phenotype, showing an increased basal I sc and a forskolin-stimulated chloride secretion that was not significantly different from the WT mice ( Figure 3b ). Thus in neonatal tracheas, the human CFTR transgene expressed from the FOXJ1 promoter was able to function as a chloride channel and restore stimulated chloride secretion to normal levels.
Expression of human CFTR in nasal epithelia
In contrast to the trachea, nasal epithelia of CF mice exhibit a clear defect in cAMP-mediated chloride secretion and a hyperabsorption of sodium as measured by the nasal potential difference (PD) technique. 21, 22 To determine if the expression of human CFTR from the FOXJ1 promoter was sufficient to correct the bioelectric defects observed in the nasal cavity of CF mice, additional experiments focused on the nasal epithelia of the FOXJ1/CFTR transgenic CF animals. Analysis of RNA by RT-PCR again confirmed the expression of human CFTR in nasal tissue isolated from the transgenic animals. The level of human CFTR mRNA in nasal epithelia was compared to the level of endogenous mouse CFTR mRNA in WT animals and found to be approximately the same (B250 copies/ng RNA, data not shown). Thus the relative expression of human CFTR was lower than that observed in tracheal tissue, whereas the level of murine CFTR expression in the nasal cavity was slightly higher. The nasal epithelium contains respiratory and olfactory cells that express murine CFTR, 23 whereas the FOXJ1 promoter targets only the respiratory tissue. Therefore, the presence of contaminating olfactory cells in our samples would dilute the level of FOXJ1 expressed CFTR. However, the overall level of human CFTR in the tissue sampled appears similar to the level of endogenous murine CFTR.
Immunoprecipitation with anti-CFTR antibodies again demonstrated production of full-length human CFTR protein in transgenic, but not WT animals. To obtain an estimate of the amount of protein produced, cell lysates from Calu-3 cells, a lung carcinoma cell line that expresses high levels of CFTR, 24 were compared to the signal obtained from nasal tissue by western blotting. These experiments indicated that the level of human CFTR in crude nasal epithelia from the transgenic mice was B4-fold less than that of the Calu-3 cells ( Figure 4 ). As Calu-3 cells have been reported to express high levels of CFTR protein, the level of human CFTR in the Figures 1A  and B ). CFTR has been reported to associate with ezrin, 25 and these data further demonstrate that the product of the transgene is targeted to the apical region of the ciliated cell. No staining above background was observed in the olfactory epithelia.
Nasal PD measurements in CFTR null mice expressing CFTR from the FOXJ1 promoter
The above experiments clearly demonstrated that the FOXJ1 promoter construct was directing the expression of human CFTR in the murine nasal epithelia. Unexpectedly, measurements of nasal PD in the FOXJ1/CFTR transgenic CFTR null animals by an investigator blinded to the animal's genotype revealed no significant change in baseline PD compared to non-transgenic CFÀ/À mice ( Figure 6 ), indicating that hyperabsorption of sodium was still present. Furthermore, the transgenic animals also showed no chloride diffusion potential in response to perfusion of a low chloride solution, similar to the CFÀ/À animals ( Figure 6 ). This indicates that the defect CFTR expression in murine ciliated cells LE Ostrowski et al in chloride secretion observed in CFÀ/À animals was still present in the transgenic animals. In comparison, the CF heterozygotes responded with a significant hyperpolarization of PD in response to perfusion of a low chloride secretion. Similar results were obtained with both independently derived lines, reducing the possibility that these results were due to an insertion phenomenon. These results demonstrate that although the FOXJ1 promoter was successfully driving the expression of the human CFTR transgene and the mature CFTR protein was readily detected in nasal epithelia by immunoprecipitation, western blotting and immunochemistry, the exogenous CFTR did not correct the nasal PD measurements.
Analysis of CFTR transcript structure
The structure of the CFTR protein is complex, and many different inactivating mutations have been identified. To confirm that the FOXJ1/CFTR transgene was producing the correct, full-length CFTR protein, the mRNA was further analyzed by a combination of RT-PCR and sequencing. First, the coding region of the human CFTR mRNA was amplified using over-lapping primers and the PCR products were sequenced. This analysis confirmed that the sequence of the expressed transgene was identical to that of the inserted CFTR cDNA. Using a combination of 5 0 -and 3 0 -rapid amplification of cDNA ends (RACE), the sequences of the 5 0 and 3 0 ends of the expressed mRNA were also examined. The sequence of the 3 0 end was as expected from the design of the transgenic construct, including the expected SV40 polyadenylation signal. However, the 5 0 end of the mRNA differed from the transcript predicted based on the data Figure 4 Expression of human CFTR in nasal epithelia. Nasal epithelial tissue was dissected from FOXJ1/CFTR transgenic mice and WT animals, and analyzed by western blotting with monoclonal antibody 596. Different amounts of Calu-3 cell lysate were loaded as a control. The amount of each sample loaded (in micrograms) is indicated. CFTR, cystic fibrosis transmembrane conductance regulator. 26 due to initiation at a site upstream of the predicted start site and the presence of an additional intron in the untranslated region of the FOXJ1 gene ( Supplementary Figure 2A) . Thus the expressed transcript contains approximately 180 bp of additional upstream sequence and the additional 550 bp intron (which is removed from the mRNA) before continuing with the predicted sequence 45 bp downstream from the originally predicted transcription start site (Supplementary Figure 2B) . Searching the current version of the NCBI nucleotide database identified several transcripts for FOXJ1, which initiate at the identical position and also demonstrated removal of the additional intron (for example, BC046460), indicating that the original sequence was most probably the result of a truncated transcript. Importantly, the additional 5 0 sequence does not alter the predicted coding sequence, indicating that the CFTR protein produced in the transgenic animals should function as WT.
Discussion
Although CF affects multiple organs in patients afflicted with this disease, the major cause of morbidity and mortality is attributed to lung infections. For this reason, gene transfer efforts have focused on the pulmonary epithelium as the primary target tissue. Although the pathogenesis of CF lung disease has been the subject of intense study, the distribution and function of the CFTR protein in the airway remains unclear. In human nasal and lower airways, it has been reported by several investigators that CFTR is present predominantly at the apical surface of ciliated cells. [5] [6] [7] In a recent report, targeting expression of CFTR to ciliated cells using a parainfluenza virus was demonstrated to correct several features of the CF phenotype in vitro.
27 Thus a ciliated cell-specific promoter may be useful to both drive expression of CFTR in the correct cell type and also to limit expression in non-target tissue.
In this study, a fragment of the FOXJ1 promoter that has previously been shown to drive expression specifically in ciliated cells 15, 28, 29 was used to target the expression of CFTR in a murine model of CF. RNA analysis demonstrated that the FOXJ1 promoter successfully targeted the expression of CFTR to the ciliated epithelium of the airways, and the level of mRNA was greater than or equal to the level of endogenous mouse CFTR. Western blotting and immunoprecipitation demonstrated the production of abundant full-length protein that was recognized by highly specific antibodies, and immunostaining demonstrated expression of CFTR specifically in the ciliated cells of the tracheal and nasal airways. Thus the FOXJ1 promoter fragment is capable of maintaining its ciliated cell-specific pattern of expression when driving the large CFTR transgene, and will be useful for targeting expression of other genes to this cell type.
In addition to studying the expression of CFTR from the FOXJ1 promoter, we also investigated whether the expression of human CFTR specifically in the ciliated cells would functionally correct the ion transport defects that are observed in the CF mouse airways. Targeted deletion of the CFTR gene to generate a mouse model for CF was first reported by two groups in 1992. 16, 30 In contrast to the phenotype of human CF, these mice displayed no overt symptoms of pulmonary pathology, instead suffering from severe intestinal disease. Several additional murine models of CF have been developed using different targeting strategies, and all of these demonstrate a similar, though not identical, phenotype. 21, 22 The lack of an obvious pulmonary phenotype in the CF mice has been largely attributed to the presence of an alternative chloride channel present in murine airway epithelia that is believed to compensate for the lack of functional CFTR in this tissue. Thus it is difficult to distinguish CF mice from WT mice on the basis of bioelectric studies of isolated trachea. However, in isolated tracheas from neonatal animals, the response to forskolin induced changes in I sc clearly discriminate between CF and WT animals. This result indicates that the regulation of chloride secretion is different between neonatal and adult trachea. The mechanism responsible for this difference is at present unknown, although it has been reported that in sheep and human, CFTR expression is higher in fetal airways than in adults. 9 Importantly, neonatal trachea from CF mice expressing the FOXJ1/CFTR transgene demonstrated an increase in I sc following forskolin treatment equivalent to WT, demonstrating that under these conditions, expression of CFTR from the FOXJ1 promoter was sufficient for correction of Cl À secretion. In contrast to the tracheal epithelium, the nasal epithelium of the CF mouse reproduces the bioelectric phenotype of human CF lungs and nasal cavity, demonstrating both an increased basal PD, due to sodium hyperabsorption, and little or no cAMP-stimulated chloride secretion. Thus the nasal epithelium of the CF mouse has been the target tissue for numerous pharmacological and gene transfer studies (for example, Ziady et al., 31 Limberis et al., 32 Grubb et al. 33 and Parsons et al.
34
). In this study, we could not detect a significant change in nasal PD as a result of CFTR expression in the ciliated cells of the nasal epithelia of the CF mouse.
There are several testable hypotheses to explain the absence of a significant restoration of nasal PD in this model. Initially, we investigated whether the CFTR transgene had been mutated during the processes of cloning and development of the transgenic mouse. However, sequencing of the mRNA using RT-PCR and overlapping primers did not identify any inactivating mutations. Although additional experiments determined that the site of initiation was different from the predicted construct, this did not alter the coding sequence of the transcript produced. Further, the transgene clearly produced abundant protein of the correct size that was recognized by highly specific antibodies against two different epitopes of human CFTR. Finally, in the neonatal trachea, the presence of the transgene restored cAMP-stimulated I sc , demonstrating that functional CFTR protein was produced. We also consistently observed an increase in forskolin-stimulated I sc in cultured tracheal epithelial cells from CF mice expressing the FOXJ1/CFTR transgene compared to cells from CF mice, indicating that under these conditions, the CFTR protein produced was functional (data not shown). These studies provide evidence that the transgene results in the production of a full-length, WT CFTR protein that is capable of functioning as a cAMP-regulated chloride channel.
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A second possible reason for the lack of a significant change in nasal PD in the transgenic CF mice is that there may be significant differences between the mouse and human CFTR proteins. Human and mouse CFTR share only 78% identity at the amino acid level, 35 and there are studies that have identified differences in channel properties between murine and human CFTR. 36 It has also been reported that the interaction of mouse and human CFTR with ENaC is species specific. 37 Thus it is possible that the human CFTR, due to sequence differences, does not function properly in mouse cells under all conditions. This could be the result of altered glycosylation, mis-localization as a result of altered binding to other proteins, or a failure to be activated by the murine signaling (kinase) pathways. It is interesting to note that in other studies, expression of the human CFTR cDNA in murine models did not restore full function. Thus Rozmahel et al., 38 used a 'knock-in' strategy to insert the human CFTR cDNA into the first exon of the murine CFTR gene. These mice showed no improvement in intestinal pathology or survival compared to CFTR null mice generated in a similar manner, although measurements of nasal PD were restored by expression of the human CFTR. In contrast, expression of a human CFTR cDNA from the fatty acid-binding protein promoter resulted in only limited correction of intestinal bioelectric properties while providing a significant improvement in intestinal pathology. 39 Therefore it remains unclear at what level and in what cell types the human CFTR protein can function to replace the endogenous mouse protein. To determine if the lack of significant correction of nasal PD observed in these studies is the result of species-specific differences between mouse and human CFTR, transgenic animals expressing murine CFTR under the control of the FOXJ1 promoter fragment have been developed. Preliminary studies of these animals also demonstrate no significant change in nasal PD compared to CF mice. Therefore, it is unlikely that the lack of significant correction in the FOXJ1/CFTR transgenic mice is due to species-specific differences in the CFTR protein.
A third possibility is that correction of nasal PD in the CF mouse requires the expression of CFTR in additional cell types. The murine nasal cavity is a complex tissue, containing approximately 50% olfactory epithelia in addition to respiratory, squamous and transitional epithelia. If the bioelectrics of the murine nasal respiratory (that is, ciliated) epithelia resemble those of the murine trachea, the respiratory epithelia may not be the major determinant of the CF phenotype. As described above, CFTR-deficient mice do not display any gross pulmonary disease, and we cannot distinguish CF from WT mice on the basis of bioelectric measurements on isolated tracheas from adult animals. CFTR expression in the murine airways has been demonstrated at the RNA level by PCR (this study) and in situ techniques; 23 however, the level of CFTR in murine lower airways is very low. [21] [22] [23] In addition, these methods lack the sensitivity to distinguish between cell types. Although antibodies specific for murine CFTR have been reported, 40 to our knowledge, the localization of endogenous murine CFTR protein in native airway tissue has not been described. Direct evidence for the expression of CFTR in murine ciliated cells comes from patch-clamp studies of isolated ciliated cells; however, in these studies, it was necessary to pretreat with forskolin, dibutyryl cAMP and 3-isobutyl-1-methylxanthine for 424 h before CFTR currents could be detected, again suggesting that the activity of endogenous CFTR is very low. 41 Thus, there appears to be little functional CFTR in the trachea of adult mice. If the respiratory epithelium of the nasal cavity is similar to that of the lower airways, there may also be little CFTR function in this epithelium.
In contrast, analysis of ion transport protein expression by in situ hybridization has suggested a higher level of several transporters, including CFTR and ENaC, in olfactory epithelium compared to respiratory epithelium in the mouse nasal cavity. 23 In addition, we have observed that the olfactory epithelia in CF mice undergo a severe and progressive degeneration, 42 and that isolated CF olfactory epithelia exhibit a much higher rate of Na + absorption than isolated CF respiratory epithelia (unpublished observation). Nasal PD measurements at different levels of the nasal cavity (olfactory or respiratory) have been shown to generate similar responses; 43 however, because the surface of the nasal epithelia is connected by the overlaying fluid, it is not clear that nasal PD measurements can be used to determine the contribution of specific cell types to the overall PD. Together, the above studies suggest that, in the mouse, CFTR function is greater in olfactory epithelia than in respiratory epithelia. Thus expression of exogenous CFTR specifically in the ciliated cells of the CF mouse may not result in a significant change in nasal PD if other cell types (that is, olfactory) are dominating the bioelectrics of this tissue.
Our results have important implications for studies using the murine nasal epithelia as a model for CF. Clearly the nasal epithelia of the CF mouse reproduce the bioelectrics of human airways and will continue to be a valuable model for testing CF therapies. For example, in studies utilizing drugs to increase the correct processing of DF508, the correction of nasal PD represents a sensitive, functional, endpoint. However, the metabolism of a particular compound may be different between olfactory and respiratory epithelia, and this should be considered when designing/interpreting experiments. Similarly, our results have important implications for gene therapy studies. Although several studies have reported correction of the abnormal nasal PD in CF mice using gene transfer protocols, these studies did not attempt to target a specific cell type. [31] [32] [33] [34] In fact, it has been reported that the olfactory epithelia is more susceptible to gene transfer by adenovirus than the respiratory epithelia, 44, 45 and in one study, it was clearly demonstrated that both respiratory and olfactory epithelia were transduced. 31 To restore normal nasal bioelectrics to the CF mouse, correction of both the olfactory and the respiratory epithelia may be required. If the bioelectric properties of murine nasal and tracheal tissue are determined by the properties of multiple cell types, gene transfer studies targeting only a single cell type, such as the present, may produce little or no correction of PD. The use of other cell type-specific promoters (that is, olfactory) to drive CFTR expression in CF mice will provide additional insight into the function of CFTR in the mouse nasal cavity. This study also highlights the importance of measuring function in addition to expression to determine the efficacy of gene transfer protocols. Further studies of the distribution and function of CFTR in the different regions of the murine nasal cavity are necessary to understand the similarities and differences relative to human airways.
Materials and methods
Generation of FOXJ1/CFTR transgenic animals
The transgenic construct was prepared by inserting the cDNA for human CFTR in the previously described plasmid containing the FOXJ1 promoter. 15 The construct was injected into the pronuclei of C57/Bl6 X C3H hybrid embryos and implanted into pseudopregnant recipient females. From the first injection, a single line was obtained that was extensively studied. A second round of injection (into C57Bl6 X DBA hybrid embryos) and screening yielded three positive founders, of which one was expanded and used to repeat most of the studies described. The two lines produced essentially identical results. Both lines were maintained as mixed strains and were bred to the mixed strain CF line, Cftr tm1Unc , to generate animals used for these studies. Littermates of the same age were used whenever possible. Animals were routinely genotyped by PCR using tail DNA. Animal studies were carried out under protocols approved by the University of North Carolina Institutional Animal Care and Use Committee.
RT-PCR analysis of CFTR expression
Total RNA was isolated from freshly isolated mouse tissues using the RNeasy kit (Qiagen Inc., Valencia, CA, USA) and reverse transcribed into cDNA using Superscript (Invitrogen, Carlsbad, CA, USA). PCR was performed using standard procedures and Amplitaq Gold (Applied Biosystems, Foster City, CA, USA). Controls included amplifications performed on samples prepared identically with no reverse transcriptase (ÀRT) and amplifications performed with no added substrate (water control). Primers used to amplify human CFTR in Figure 1a were 5 0 -TGACACACTCAGTTAACCAAGGTCAG-3 0 and 5 0 -CCTCTGAAGAATCCCATAGCAAGCAA-3 0 . For quantification of mouse and human CFTR, a standard was first prepared by amplifying the target fragment of the mouse or human CFTR cDNA. The product was purified, quantitated and diluted to a range of 5 Â 10 À6 to 5 Â 10 À9 ng/ml and used to produce a standard curve. Quantitative PCR was performed using a Lightcycler PCR machine and a Lightcycler Fast start DNA master SYBR Green I kit from Roche (Roche Applied Science, Indianapolis, IN, USA). Each reaction was performed in duplicate on RNA isolated from three separate animals. The average crossover point was determined using the Roche software and converted to copy number per ng of total RNA by comparison to the standard curve. Primers for human CFTR were as above and primers for mouse CFTR were 5 0 -ACGTTCACACCCAACTCAGGCTCC-3 0 and 5 0 -GAAGCAGCCACCTCAACCAGAAAAA-3 0 .
Analysis of human CFTR protein expression
Immunoprecipitation of CFTR was performed using procedures similar to those previously described. 18 Briefly, tracheas were removed from FOXJ1/CFTRpositive and -negative animals and homogenized in M-PER lysis solution (Pierce, Rockford, IL, USA) containing proteinase inhibitors. For nasal studies, the epithelia lining the septum and the lateral wall were removed by dissection and dissolved in M-PER. Following centrifugation, the supernatant was collected, protein concentration was determined (bicinchoninic acid (BCA) method; Pierce) and the samples were stored at À801C. 
Immunolocalization of CFTR
FOXJ1/CFTR transgenic mice and WT littermates were euthanized by CO 2 asphyxiation and selected tissues were surgically removed. The isolated tissues were rapidly frozen in optimal cutting temperature compound (OCT; Sakura Finetek Co., Torrance, CA, USA) using solid CO 2 . Thin frozen sections (8 mm) were prepared for immunostaining and stored at À801C. Frozen tissue sections were fixed at room temperature in 4% paraformaldehyde (PFA) and then dehydrated briefly in 100% ethanol and rinsed with phosphate-buffered saline (PBS) containing Ca 2+ and Mg 2+ (PBS+). Tissues were incubated in goat anti-mouse IgG Fab fragment (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) to block endogenous binding sites and fixed briefly with 4% PFA, washed with PBS+ and blocked in 10% normal goat serum (NGS, Jackson ImmunoResearch Laboratories). Sections were incubated at 41C overnight with antihuman CFTR antibody 570 (ascites fluid, generously provided by Dr J Riodan) or mouse IgG both diluted at 1:1000. For identification of ciliated cells, sections were incubated with mouse monoclonal anti-b-tubulin FITC conjugate (Sigma, St Louis, MO, USA). Primary antibodies were diluted in 10% NGS. For immunodetection of human CFTR, slides were incubated with biotin-SPconjugated goat anti-mouse diluted at 1:2000, followed by Texas-Red dye-conjugated streptavidin diluted at 1:500, both from Jackson ImmunoResearch. All secondary and tertiary antibodies were diluted in washing solution (1% NGS). Slides were washed with PBS+/ 0.05% Tween and mounted using Vecta-Shield mounting medium containing 4,6-diamidino-2-phenylindole to label nuclei (Vector Laboratories, Burlingame, CA, USA) and sealed with nail polish.
Image acquisition and analysis were performed on a Leica SP2 AOBS upright laser scanning confocal microscope with a Â 63/1.4 oil immersion Leica lens (Leica Microsystems, Heidlberg, Germany). Scanning of epithelia in tissue sections was performed in the XY axis using the following laser sources: 364 UV, 488 Ar and 568 nm Kr). Laser and scanning settings remained constant for each data acquisition in different experiments. Images were assembled using the identical procedures for control and experimental tissue with Adobe Photoshop software (Adobe Systems Inc., San Jose, CA, USA).
Ussing chamber studies
All measurements were performed by an investigator who was blinded to the genotype of the animals. Adult mice (both sexes) were euthanized by CO 2 inhalation and the tracheas were immediately removed and mounted in an Ussing chamber as described previously. 46 When the tracheas of neonatal mice were studied, the mice were euthanized by an overdose of ketamine/xylazine. In all Ussing chamber studies, the tissues were bathed bilaterally in Krebs bicarbonate buffer. All drugs were added sequentially as indicated in the text or figure legend.
Nasal PD studies
All measurements were again performed by an investigator who was blinded to the genotype of the animals. For the nasal PD measurements, the mice were anesthetized with a combination of ketamine/xylazine (86.95 and 9.89 mg/kg, respectively). The body temperature of the mouse was continually monitored with a rectal thermocouple (Physitemp) and maintained at 371C with a heat lamp. All details of the nasal PD technique have been published previously, 33 the only modification being that the perfusion flow rate was reduced to 0.5 ml/min. The basal PD was obtained by perfusing the nasal epithelia with a physiological buffer (TES) and then the solution was switched to TES buffer containing amiloride (10 À4 M). After reaching a steady state, the solution was changed to a low Cl À buffer containing amiloride. When solutions were switched, the new solution reached the mouse's nose within B2-3 min.
Analysis of the FOXJ1/CFTR mRNA
Total RNA was isolated from tracheal or nasal cells cultured from transgenic positive or negative mice using RNeasy reagents and protocols from Qiagen. RT-PCR was performed as above using a series of overlapping primers (available on request) that covered the entire CFTR coding region using Expand High Fidelity PCR System (Roche Applied Science). Products were purified (Qiaquick; Qiagen) and sequenced directly by the UNC-CH Genome Analysis Facility. For determination of the 5 0 and 3 0 ends of the CFTR mRNA, RACE was performed using the GeneRacer kit (Invitrogen) according to the manufacture's protocols. Gene specific primers for 5 0 -RACE were 5 0 -CATTCTCCCTAGCCCAGCCTGAAA-3 0 and 5 0 -AGTGCCACTTGCAAAGGAGCGATC-3 0 , and for 3 0 -RACE were 5 0 -GTGGAGGAAAGCCTTTGGAGTGAT 3 0 and 5 0 -TAAGCCATGGCCACAAGCAGTTG-3 0 . Major products were gel-purified, cloned into TOPO vector (Invitrogen) and sequenced at the UNC-CH Genome Analysis Facility.
